[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

GB0514967D0 - Therapeutic compositions that alter the immune response - Google Patents

Therapeutic compositions that alter the immune response

Info

Publication number
GB0514967D0
GB0514967D0 GBGB0514967.9A GB0514967A GB0514967D0 GB 0514967 D0 GB0514967 D0 GB 0514967D0 GB 0514967 A GB0514967 A GB 0514967A GB 0514967 D0 GB0514967 D0 GB 0514967D0
Authority
GB
United Kingdom
Prior art keywords
alter
immune response
therapeutic compositions
therapeutic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB0514967.9A
Other versions
GB2413960A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALTAREX Corp
ALTAREX Inc
Original Assignee
ALTAREX Corp
ALTAREX Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALTAREX Corp, ALTAREX Inc filed Critical ALTAREX Corp
Priority claimed from GB0324503A external-priority patent/GB2390811B/en
Publication of GB0514967D0 publication Critical patent/GB0514967D0/en
Publication of GB2413960A publication Critical patent/GB2413960A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB0514967A 2001-03-21 2002-03-08 Treating ovarian cancer Withdrawn GB2413960A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27759901P 2001-03-21 2001-03-21
GB0324503A GB2390811B (en) 2001-03-21 2002-03-08 Therapeutic compositions that alter the immune response

Publications (2)

Publication Number Publication Date
GB0514967D0 true GB0514967D0 (en) 2005-08-24
GB2413960A GB2413960A (en) 2005-11-16

Family

ID=35169359

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0514967A Withdrawn GB2413960A (en) 2001-03-21 2002-03-08 Treating ovarian cancer

Country Status (1)

Country Link
GB (1) GB2413960A (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0700305B1 (en) * 1993-05-27 2000-01-26 Wagner, Uwe, Dr.med. Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
US5871941A (en) * 1995-07-28 1999-02-16 Univ British Columbia Method of testing expression of CA125 antigen in cultured ovarian surface epithelial cells to identify and monitor individuals having a predisposition to develop ovarian cancer
DK0910407T3 (en) * 1996-05-15 2003-06-16 Altarex Inc Method and composition for reconstitution of multiepitope antigens to initiate an immune response

Also Published As

Publication number Publication date
GB2413960A (en) 2005-11-16

Similar Documents

Publication Publication Date Title
EP1461074A4 (en) Agents for enhancing the immune response
GB2364642B (en) Compositions for enhancing the immune response
GB2390811B (en) Therapeutic compositions that alter the immune response
AU2002365093A8 (en) Therapeutic compositions
IL139832A0 (en) Therapeutic compositions that produce an immune response by altering the antigen
GB0109428D0 (en) Therapeutic compositions
GB0124710D0 (en) Therapeutic composition
AU2002334631A8 (en) Immune response associated proteins
GB0514967D0 (en) Therapeutic compositions that alter the immune response
GB2372247B (en) Kiln furniture or the like
GB0112267D0 (en) The pagekeeper
GB0124935D0 (en) The safetycom
GB0103378D0 (en) The balls
GB0109114D0 (en) Stimulation of the immune system
AU2002362494A1 (en) Tumor-peptide antigens from the human prdi-bf1-protein
GB2371998B (en) The values doll
GB0114955D0 (en) Therapeutic compositions
GB0117325D0 (en) Therapeutic compositions
GB0116847D0 (en) Therapeutic compositions
GB0128837D0 (en) The Unicorn
GB0118939D0 (en) The bond
GB0207816D0 (en) The shock-stopper
GB0124746D0 (en) The chopfast fingerguard
GB0100466D0 (en) The medi-disc
GB0120732D0 (en) The Fridgsaw

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)